PubMed
Impact Factor 3

Elsevier BV

Multiple Sclerosis and Related Disorders

Indexed in MEDLINE (PubMed). Published by Elsevier BV.

Multiple Sclerosis and Related Disorders publishes original research, reviews and expert opinion on multiple sclerosis and other immune mediated or infectious diseases of the central nervous system. Its scope covers clinical neurology, epidemiology, imaging, immunology, genetics, biomarkers, neuropsychology, rehabilitation and new treatments.
Reviewed byDr Robert BaxterDr Robert Baxter· Junior Clinical Fellow, Acute Medical Unit· Updated 15 Nov 2026

Publishing in Multiple Sclerosis and Related Disorders

Multiple Sclerosis and Related Disorders is published by Elsevier. It covers the understanding, diagnosis and treatment of multiple sclerosis and related immune mediated or infectious diseases of the central nervous system. Its subjects include clinical neurology, epidemiology, neurobiology, imaging, immunology, genetics, biomarkers, neuropsychology, rehabilitation and new treatments. The guide lists Original Research, Reviews, Editorials and Commentaries.

Authors can publish through the subscription route without a publication fee. Optional open access costs US$3,690 before tax, with possible institutional coverage or personalised pricing. The journal uses single anonymised peer review, normally with at least two independent reviewers. It reports 54 days from submission to a decision after review and an acceptance rate of 34%. Full length research papers normally have a 3,500 word limit, and abstracts are limited to 250 words.

Free subscriber access

Free with a subscription: the author guide in one place

Word limits, abstract lengths and fees for each article type, and a checklist before you submit. Enter your email to unlock this journal and every other guide.

  • Original Research

    Original studies that advance understanding, diagnosis or treatment of multiple sclerosis and related disorders.

    Words
    3,500
    Abstract
    250
    Figures & tables
    —
    References
    —
  • Reviews
    Words
    —
    Abstract
    —
    Figures & tables
    —
    References
    —
  • Editorials
    Words
    —
    Abstract
    —
    Figures & tables
    —
    References
    —
  • Commentaries
    Words
    —
    Abstract
    —
    Figures & tables
    —
    References
    —

The subscription route has no publication fee. Optional open access costs US$3,690 before tax, although the personalised charge may vary with country, institution or society membership. Eligible institutional agreements may cover some or all of the charge.

Before you submit

  • Keep a full length research paper within 3,500 words from the Introduction through the Discussion.
  • Provide a concise factual abstract of no more than 250 words.
  • Submit three to five highlights as a separate editable file, with no more than 85 characters in each bullet.
  • Register clinical trials at or before enrolment and include the registration number, preferably at the end of the abstract.
  • For a randomised trial, submit a CONSORT checklist and flow diagram.
  • Declare any use of generative AI in a new section before the reference list.

Present it first.

Similar journals.

Frequently asked

Is Multiple Sclerosis and Related Disorders indexed in PubMed?
Yes. Multiple Sclerosis and Related Disorders is indexed in MEDLINE, so its articles are in PubMed with a PMID.
How much does it cost to publish in Multiple Sclerosis and Related Disorders?
There is a free route: authors can publish without a fee.
Does Multiple Sclerosis and Related Disorders accept case reports?
No. Multiple Sclerosis and Related Disorders does not publish case reports.
What is the Impact Factor of Multiple Sclerosis and Related Disorders?
Multiple Sclerosis and Related Disorders states an Impact Factor of 3 for 2025.
How long does Multiple Sclerosis and Related Disorders take to decide?
About 54 days from submission to first decision.
What is the acceptance rate of Multiple Sclerosis and Related Disorders?
Multiple Sclerosis and Related Disorders states that it accepts 34% of submissions.
What kind of peer review does Multiple Sclerosis and Related Disorders use?
Single-blind peer review.

MEDLINE · Free route · First decision in 54 days

Accepted work
Original research · Literature review
Acceptance rate
34%
Peer review
Single-blind
Access
Subscription with optional open access · Subscribe ↗
Author guide

Checked against the journal’s author guide · updated 15 Nov 2026